Ustekinumab beats placebo for ulcerative colitis
International trial showed subcutaneous maintenance therapy to be effective
1st October 2019
By Clare Pain
Patients with moderate to severe ulcerative colitis are more likely to achieve clinical remission and a range of other outcomes on ustekinumab than placebo, according to the results of a phase 3 trial.